Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00259038 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

A Phase 2 study, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase
162
Enrollment target

NCT00259038 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 162 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00259038, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase
162 participants
Enrollment target

Study Summary

The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

Interventions

  • DRUG Placebo
  • DRUG Carperitide

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2004-01
Est. Completion 2006-02
Phase Phase 2

Sponsor

Daiichi Sankyo

236 total trials

What the Registry Record Tells You About NCT00259038

The ClinicalTrials.gov registry entry for NCT00259038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00259038 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00259038 about?

NCT00259038 is a clinical study titled "Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure". The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

What is the current status of trial NCT00259038?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2004-01. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00259038?

The interventions under investigation include: Placebo (DRUG), Carperitide (DRUG).

Who is sponsoring clinical trial NCT00259038?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.